CIRM Funded Clinical Trials

A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML


Colleen Delaney
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$6,922,109
Trial Stage: 
Phase 2
Trial Status: 
Not yet recruiting
Targeted Enrollment:
220
ClinicalTrials.gov ID:
Details: 

Nohla Therapeutics is testing a hematopoietic stem cell and progenitor cell therapy called NLA101 to help patients suffering from neutropenia, a condition that leaves people susceptible to deadly infections, after receiving chemotherapy for acute myeloid leukemia (AML). The company is currently launching a Phase 2 trial to test this treatment in adult AML patients that have received high-dose chemotherapy.

Design: 

Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy.

Goal: 

Evaluate effect on the rate of infections associated with Chemotherapy-Induced Neutropenia in AML patients and determine optimal dose of cell therapy.

Updates: 

Launching